Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...

Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support ...